tirzepatide mash phase 3 hits two receptors. Semaglutide hits one. The liver feels the difference. Both drugs work in MASH. The question is whether the second receptor — GIP — adds meaningful hepatic benefit beyond Pipeline of New Drug Treatment

Regarding safety, the incidence of adverse events and discontinuation rate of the study drug were greater in the tirzepatide group, but serious adverse events and hypoglycemia were lower

There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with JANUVIA or any other anti-diabetic drug

Severity of Pigmentation: Mild or superficial dullness may respond differently compared to deeper or long-standing hyperpigmentation

Those using Mounjaro and oral contraceptives are suggested to use extra barrier contraception for four weeks after beginning the treatment or increasing the dose, as GLP-1 medicines may minimize the pills effectiveness

Acetyl-L-carnitine improves cognitive functions in severe hepatic encephalopathy: a randomized and controlled clinical trial